Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-24-029181)

Names of Reporting Persons

Adjuvant Global Health Technology Fund, L.P.

Check the appropriate box if a member of a Group (see instructions)

(a) ☐ (b) ☐

Sec Use Only

Citizenship or Place of Organization

Cayman Islands

Accession Number:: 0001193125-24-029181
Form Type:: 13G Filing
Publication Date:: 2024-02-08 19:00:00

Filed By:: Adjuvant Global Health Technology Fund, L.p.
Company:: An2 Therapeutics Inc.
Filing Date:: 2024-02-09
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Adjuvant Global Health Technology Fund	2,080,051	2,080,051	2,080,051	7.0%
Adjuvant Global Health Technology Fund DE	393,449	393,449	393,449	1.3%
Adjuvant Capital GP	2,473,500	2,473,500	2,473,500	8.3%
Adjuvant Capital Management	2,473,500	2,473,500	2,473,500	8.3%

Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

AN2 Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

037326105

(CUSIP Number)

December 31, 2023

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


		SCHEDULE 13G
CUSIP No. 037326105

(1)	The calculation of the percent of class is based on 29,741,445 shares of common stock issued and outstanding as of November 2, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

Page 2 of 9


		SCHEDULE 13G
CUSIP No. 037326105

(1)	The calculation of the percent of class is based on 29,741,445 shares of common stock issued and outstanding as of November 2, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

Page 3 of 9


		SCHEDULE 13G
CUSIP No. 037326105

(1)	The calculation of the percent of class is based on 29,741,445 shares of common stock issued and outstanding as of November 2, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

Page 4 of 9


		SCHEDULE 13G
CUSIP No. 037326105

(1)	The calculation of the percent of class is based on 29,741,445 shares of common stock issued and outstanding as of November 2, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

Page 5 of 9

Item 1.

(a) Name of Issuer: This Schedule 13G (this Schedule 13G) relates to the common stock, par value $0.00001 per share (the Common Stock), of AN2 Therapeutics, Inc. (the Issuer).

(b) Address of Issuers Principal Executive Offices: The Issuers principal executive office is located at1800 El Camino Real, Suite D, Menlo Park, CA 94027.

Item 2.

(a)

Name of Person Filing: This Schedule 13G is being filed jointly by Adjuvant Global Health Technology Fund, L.P. (AGHT Fund), Adjuvant Global Health Technology Fund DE, L.P. (AGHT Fund DE), Adjuvant Capital GP, L.P. (AC GP) and Adjuvant Capital Management, L.L.C. (AC Management and together with AGHT Fund, AGHT Fund DE and AC GP, the Reporting Persons).

AC GP is the sole general partner of AGHT Fund and the sole general partner of AGHT Fund DE, and may be deemed to beneficially own the shares of Common Stock beneficially owned by AGHT Fund and AGHT Fund DE. AC Management is the sole general partner of AC GP and may be deemed to beneficially own the shares of Common Stock beneficially owned by AGHT Fund and AGHT Fund DE.

(b)

Address of Principal Business Office or, if None, Residence: The principal business address of each of the Reporting Persons, is c/o Adjuvant Capital, L.P., 500 Fifth Avenue, Suite 5120, New York, NY 10110.

(c)

Citizenship: AGHT Fund is organized under the laws of the Cayman Islands. AGHT Fund DE, AC GP and AC Management are each organized under the laws of the State of Delaware.

(d)	Title and Class of Securities: The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, par value $0.00001 per share.

(e)

CUSIP No.: 037326105

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	[_]	Broker or dealer registered under Section 15 of the Act;

(b)	[_]	Bank as defined in Section 3(a)(6) of the Act;

(c)	[_]	Insurance company as defined in Section 3(a)(19) of the Act;

(d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940;

(e)	[_]	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)	[_]	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

Page 6 of 9


(g)	[_]	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)	[_]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

(j)	[_]	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)	[_]	Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

See rows 5 through 11 of the cover pages.

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of more than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

Not applicable.

Item 8.

Identification and classification of members of the group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 7 of 9

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2024


ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P.

By: Adjuvant Capital GP, L.P., its sole general partner,
By: Adjuvant Capital Management, L.L.C., its sole general partner,
By:		/s/ Kabeer Aziz
Name: Kabeer Aziz
Title: Vice President and Secretary

ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE, L.P.

By: Adjuvant Capital GP, L.P., its sole general partner,
By: Adjuvant Capital Management, L.L.C., its sole general partner,
By:		/s/ Kabeer Aziz
Name: Kabeer Aziz
Title: Vice President and Secretary

ADJUVANT CAPITAL GP, L.P.

By: Adjuvant Capital Management, L.L.C., its sole general partner,
By:		/s/ Kabeer Aziz
Name: Kabeer Aziz
Title: Vice President and Secretary

ADJUVANT CAPITAL MANAGEMENT, L.L.C.

By:		/s/ Kabeer Aziz
Name: Kabeer Aziz
Title: Vice President and Secretary

Page 8 of 9